| Advances in the pathogenesis of adhesion development: the role of oxidative stress AO Awonuga, J Belotte, S Abuanzeh, NM Fletcher, MP Diamond, ... Reproductive sciences 21 (7), 823-836, 2014 | 84 | 2014 |
| Sox2 gene amplification significantly impacts overall survival in serous epithelial ovarian cancer J Belotte, NM Fletcher, M Alexis, RT Morris, AR Munkarah, MP Diamond, ... Reproductive Sciences 22 (1), 38-46, 2015 | 47 | 2015 |
| The role of oxidative stress in the development of cisplatin resistance in epithelial ovarian cancer J Belotte, NM Fletcher, AO Awonuga, M Alexis, HM Abu-Soud, MG Saed, ... Reproductive sciences 21 (4), 503-508, 2014 | 45 | 2014 |
| Myeloperoxidase and free iron levels: potential biomarkers for early detection and prognosis of ovarian cancer NM Fletcher, Z Jiang, R Ali-Fehmi, NK Levin, J Belotte, MA Tainsky, ... Cancer Biomarkers 10 (6), 267-275, 2012 | 37 | 2012 |
| Small bowel obstruction subsequent to Essure microinsert sterilization: a case report J Belotte, VI Shavell, AO Awonuga, MP Diamond, JM Berman, AF Yancy Fertility and sterility 96 (1), e4-e6, 2011 | 36 | 2011 |
| Specific point mutations in key redox enzymes are associated with chemoresistance in epithelial ovarian cancer NM Fletcher, J Belotte, MG Saed, I Memaj, MP Diamond, RT Morris, ... Free Radical Biology and Medicine 102, 122-132, 2017 | 32 | 2017 |
| A single nucleotide polymorphism in catalase is strongly associated with ovarian cancer survival J Belotte, NM Fletcher, MG Saed, MS Abusamaan, G Dyson, MP Diamond, ... PloS one 10 (8), e0135739, 2015 | 29 | 2015 |
| OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab MM Hardesty, TC Krivak, GS Wright, E Hamilton, EL Fleming, J Belotte, ... Gynecologic oncology 166 (2), 219-229, 2022 | 28 | 2022 |
| The role of angiogenesis in the persistence of chemoresistance in epithelial ovarian cancer O Nusrat, J Belotte, NM Fletcher, I Memaj, MG Saed, MP Diamond, ... Reproductive Sciences 23 (11), 1484-1492, 2016 | 25 | 2016 |
| Chemotherapy of vulvar cancer: a review. G Deppe, I Mert, J Belotte, IS Winer Wiener Klinische Wochenschrift 125, 2013 | 23 | 2013 |
| Platinum-based combination chemotherapy for the treatment of advanced-stage squamous cell carcinoma of the vulva J Belotte, AO Awonuga, R Bolinjkar, M Alexis, F Tabassum, G Deppe Obstetrics & Gynecology 120, 458-460, 2012 | 7 | 2012 |
| Phase II OVARIO study of niraparib+ bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab M Hardesty, T Krivak, G Wright, E Hamilton, E Fleming, J Belotte, ... Gynecologic Oncology 162, S17, 2021 | 6 | 2021 |
| Successful laparoscopic management of ruptured tubal pregnancy with an ipsilateral ectopic pelvic kidney J Belotte, J Belotte, M Alexis, AO Awonuga, TJ Aguin Case Reports in Obstetrics and Gynecology 2014, 2014 | 2 | 2014 |
| Open-label, phase 2, randomized controlled multicenter study comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in participants with … X Zeng, J Belotte, B Felicetti, A Baines, A Youssefagha, L Rojas-Espaillat, ... Gynecologic Oncology 176, S159-S160, 2023 | 1 | 2023 |
| The in-vivo effects of superoxide dismutase on the incidence and severity of post-operative adhesion development AO Awonuga, NM Fletcher, MG Saed, O Nusrat, MS Abusamaan, ... Fertility and Sterility 102 (3), e73, 2014 | 1 | 2014 |
| Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination–deficient stage III/IV … J Belotte, B Felicetti, AJ Baines, A YoussefAgha, L Rojas-Espaillat, ... Trials 25 (1), 301, 2024 | | 2024 |
| OVARIO, A Phase 2 Study of Niraparib plus Bevacizumab in Advanced Ovarian Cancer (OC) Following Front-Line Platinum-Based Chemotherapy (CT) with Bevacizumab (bev): Updated Analysis MM Hardesty, J Grabowski, T Krivak, GS Wright, E Hamilton, EL Fleming, ... ONCOLOGY RESEARCH AND TREATMENT 45 (SUPPL 3), 113-113, 2022 | | 2022 |
| OVARIO, A Phase 2 Study of Niraparib+ Bevacizumab in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy with Bevacizumab: Updated Analysis (039) M Hardesty, T Krivak, G Wright, E Hamilton, E Fleming, J Belotte, ... Gynecologic Oncology 166, S27-S28, 2022 | | 2022 |
| Chemoresistant Ovarian Cancer Cells Manifest Lower Vascular Endothelial Growth Factor and Hypoxia Inducible Factor-1 alpha: A Potential Survival Mechanism. O Nusrat, J Belotte, NM Fletcher, MG Saed, MP Diamond, GM Saed REPRODUCTIVE SCIENCES 23, 178A-178A, 2016 | | 2016 |
| The role of oxidative stress in the establishment of resistance to cisplatin in epithelial ovarian cancer cells J Belotte Wayne State University, 2016 | | 2016 |
